healthandpharma1 天
FDA Greenlights Revumenib for Relapsed Leukemia Treatment, First Administered at FCS
The U.S. Food and Drug Administration (FDA) has approved revumenib, a pioneering drug for relapsed or refractory acute ...
healthandpharma2 天
FDA Approves Ziihera as the First Dual HER2-Targeted Therapy for Biliary Tract Cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii), a novel therapy for ...
healthandpharma3 天
How the ARANOTE Trial Results Could Advance Prostate Cancer Treatment
ONCOLife proudly presents an exclusive interview with Dr. Iris Kuss, VP and Global Development Lead Oncology at Bayer. In ...
healthandpharma4 天
How Oncolytic Viruses Could Be a New Frontier in Transforming Cancer Treatment
Oncolytic viruses are a very promising class of therapeutic agents, with a broad range of types. In this exclusive interview ...
healthandpharma5 天
Cambridge Researchers Launch Groundbreaking Study to Uncover Cancer Survival Secrets
Researchers from Cambridge University Hospitals, in collaboration with the NHS Health Research Authority, have launched the ...
healthandpharma15 天
FDA Approves MI Cancer Seek Test as a Groundbreaking Tool for Targeted Cancer Therapy
Caris Life Sciences announced that the U.S. Food and Drug Administration (FDA) has granted approval for the MI Cancer Seek™ test, the first diagnostic assay to simultaneously use Whole Exome and Whole ...
healthandpharma16 天
Overcoming Resistance in Cancer Treatment with Cytokine Therapies
Cytokine therapies have the potential to transform cancer treatment by enhancing the body’s immune response to fight cancer more effectively. In our interview with Caroline Loew, Ph.D., CEO of Mural ...
healthandpharma17 天
IMUNON’s Novel Immunotherapy IMNN-001 Enhances Survival in Ovarian Cancer
IMUNON’s Phase 2 OVATION 2 study shows promising results for its immunotherapy, IMNN-001, in advanced ovarian cancer. Combined with standard chemotherapy, IMNN-001 improved overall survival by 35% and ...